Directive 2004/23/EC of the European Parliament and of the Council of 31 March 2004 on setting standards of quality and safety for the donation, procurement, testing, processing, preservation, storage and distribution of human tissues and cells

Print Options
PrintThe Whole
Directive
PrintThe
Annexes
only
Changes over time for: Directive 2004/23/EC of the European Parliament and of the Council (Annexes only)


Timeline of Changes
This timeline shows the different versions taken from EUR-Lex before exit day and during the implementation period as well as any subsequent versions created after the implementation period as a result of changes made by UK legislation.
The dates for the EU versions are taken from the document dates on EUR-Lex and may not always coincide with when the changes came into force for the document.
For any versions created after the implementation period as a result of changes made by UK legislation the date will coincide with the earliest date on which the change (e.g an insertion, a repeal or a substitution) that was applied came into force. For further information see our guide to revised legislation on Understanding Legislation.
Status:
EU Directives are published on this site to aid cross referencing from UK legislation. Since IP completion day (31 December 2020 11.00 p.m.) no amendments have been applied to this version.
ANNEXU.K.INFORMATION TO BE PROVIDED ON THE DONATION OF CELLS AND/OR TISSUES
A.Living donorsU.K.
1.The person in charge of the donation process shall ensure that the donor has been properly informed of at least those aspects relating to the donation and procurement process outlined in paragraph 3. Information must be given prior to the procurement.U.K.
2.The information must be given by a trained person able to transmit it in an appropriate and clear manner, using terms that are easily understood by the donor.U.K.
3.The information must cover: the purpose and nature of the procurement, its consequences and risks; analytical tests, if they are performed; recording and protection of donor data, medical confidentiality; therapeutic purpose and potential benefits and information on the applicable safeguards intended to protect the donor.U.K.
4.The donor must be informed that he/she has the right to receive the confirmed results of the analytical tests, clearly explained.U.K.
5.Information must be given on the necessity for requiring the applicable mandatory consent, certification and authorisation in order that the tissue and/or cell procurement can be carried out.U.K.
B.Deceased donorsU.K.
1.All information must be given and all necessary consents and authorisations must be obtained in accordance with the legislation in force in Member States.U.K.
2.The confirmed results of the donor's evaluation must be communicated and clearly explained to the relevant persons in accordance with the legislation in Member States.U.K.
Back to top